Listen
JAKAVI (ruxolitinib), protein kinase inhibitor
ONCOLOGY - New indication
Opinions on drugs -
Posted on
Feb 29 2016
Reason for request
Extension of inclusion
Minor improvement in second-line treatment of polycythemia vera.
JAKAVI now has Marketing Authorisation in the treatment of adults with polycythemia vera who are resistant or intolerant to hydroxyurea.
It provides a minor improvement in the short term, due to better safety and an improvement of symptoms. There are no long-term safety data.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| minor |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
